Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEP 4199 (Primary)
Indications Bipolar I disorders; Major depressive disorder
Focus Proof of concept; Therapeutic Use
Sponsors Sunovion Pharmaceuticals

Most Recent Events

01 Jan 2022 Results published in the Journal of Affective Disorders
06 Jul 2020 According to a Sunovion Pharmaceuticals media release, it will present the full study data and discussing them with the scientific community at future medical meetings.
06 Jul 2020 Topline Results(n=337) published in Sunovion Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com